G. Jiang

发表

Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.

S. Biswas, Bei B. Zhang, Zhihua Li, 2004, The Biochemical journal.

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Michael E. Lassman, N. Thornberry, Gaochao Zhou, 2009, Diabetes.

Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1.

Margaret S. Wu, T. Doebber, D. Szalkowski, 2005, The Journal of clinical investigation.

A novel series of indazole-/indole-based glucagon receptor antagonists.

S. Qureshi, Bei B. Zhang, G. Salituro, 2015, Bioorganic & medicinal chemistry letters.

Development of a novel GLUT4 translocation assay for identifying potential novel therapeutic targets for insulin sensitization.

M. Ferrer, J. Berger, F. Santini, 2009, The Biochemical journal.

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

D. Moller, N. Thornberry, S. Conarello, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor γ (PPAR γ ), decreases inhibitory serine phosphorylation of IRS1 invitro and invivo

Bei B. Zhang, Li Zhihua, Q. Dallas-yang, 2003 .

Salicylic Acid Reverses Phorbol 12-Myristate-13-Acetate (PMA)- and Tumor Necrosis Factor α (TNFα)-induced Insulin Receptor Substrate 1 (IRS1) Serine 307 Phosphorylation and Insulin Resistance in Human Embryonic Kidney 293 (HEK293) Cells*

D. Moller, Bei B. Zhang, Franklin Liu, 2003, The Journal of Biological Chemistry.

A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.

D. Moller, V. Ding, S. Qureshi, 2004, Diabetes.

Discovery of potent, orally active benzimidazole glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2008, Bioorganic & medicinal chemistry letters.

Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.

V. Ding, S. Qureshi, D. Szalkowski, 2005, Bioorganic & medicinal chemistry letters.

Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist

Margaret S. Wu, S. Qureshi, J. Mu, 2012, PloS one.

Detection of Glucagon-Dependent GTPγS Binding in High-Throughput Format

S. Qureshi, Bei B. Zhang, Q. Dallas-yang, 2002 .

Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.

J. Fenyk-Melody, S. Qureshi, D. Szalkowski, 2004, European journal of pharmacology.

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

S. Qureshi, S. Xu, Bei B. Zhang, 2012, Journal of medicinal chemistry.

Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity.

I. Wang, J. Berger, P. Lu, 2009, European Journal of Pharmacology.

Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo.

Margaret S. Wu, I. Wang, J. Berger, 2009, European journal of pharmacology.

Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists.

D. Gerhold, D. Holder, J. Berger, 2002, Endocrinology.

A miniaturized cell-based fluorescence resonance energy transfer assay for insulin-receptor activation.

Shane D. Marine, Erica M. Stec, M. Ferrer, 2006, Analytical biochemistry.

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

V. Ding, S. Qureshi, D. Szalkowski, 2011, Bioorganic & medicinal chemistry letters.

GLP-1/GCGR dual agonism reverses obesity in mice Short-running title: Dual GLP-1/GCGR agonist for the treatment of obesity

Michael E. Lassman, N. Thornberry, Gaochao Zhou, 2009 .

Glucagon and regulation of glucose metabolism.

Bei B. Zhang, Guoqiang Jiang, Bei B Zhang, 2003, American journal of physiology. Endocrinology and metabolism.

Ansuman Bagchi, Alex Elbrecht, Arthur Fridman, 2022 .

Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists.

Margaret S. Wu, J. Berger, D. Moller, 2002, Diabetes.

Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes.

Bei B. Zhang, G. Jiang, 2002, Frontiers in bioscience : a journal and virtual library.

Modulation of insulin signalling by insulin sensitizers.

G. Jiang, B. Zhang, B. Zhang, 2005, Biochemical Society transactions.

Downstream Signaling Pathways in Mouse Adipose Tissues Following Acute In Vivo Administration of Fibroblast Growth Factor 21

Margaret S. Wu, R. Hendrickson, C. Paweletz, 2013, PloS one.

Dipeptidyl Peptidase‐4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP‐1

J. Holst, B. Weiss, N. Thornberry, 2010, Clinical pharmacology and therapeutics.

Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1.

Margaret S. Wu, T. Doebber, D. Szalkowski, 2005, The Journal of clinical investigation.

Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity.

I. Wang, J. Berger, P. Lu, 2009, European journal of pharmacology.